Repligen Corporation · NASDAQ:RGEN

Repligen — Merger or Acquisition (July 2026)

14 slides from Repligen's merger presentation, Jul 22, 2026

  1. Slide 1: Repligen to Acquire BioLife Solutions

    July 22, 2026 Repligen to Acquire BioLife Solutions Exhibit 99.2

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Cautionary Statement Regarding Forward-Looking Statements Statements included in this presentation, which are not historical in nature or do not relate to current facts, are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor

  3. Slide 3: We continue to execute diligently and delivered another excellent quarter

    We continue to execute diligently and delivered another excellent quarter Second Quarter: ~12% reported or 13% organic revenue growth(1), strong margin expansion Full details to be provided on July 28th Strong momentum in our existing business and high-confidence in our future growth Excited to anno

  4. Slide 4: Acquisition Highlights

    Acquisition Highlights Signed agreement to acquire BioLife Solutions for $31/share … targeted to close in Q4-26 (1) Excited to welcome ~160 associates to the RGEN team at closing … shared culture of innovation BioLife is a scaled, highly-differentiated cell processing tools leader for the cell thera

  5. Slide 5: Strong Strategic Rationale with Immediate Value Creation Opportunity

    Fast-tracks Cell Therapy (CT) Leadership Adds a differentiated platform in a rapidly growing market Enhances cell therapy capabilities Creates Expected Long-term Value for Shareholders Accelerates profitable growth Adds new vertical for accretive M&A Expands Robust Customer Solutions Offering Create

  6. Slide 6: Fully Aligned with Repligen Acquisition Criteria

    Fully Aligned with Repligen Acquisition Criteria Technology First: à Differentiated cell processing platform 1 Strategic Relevance: à Strengthens presence in growing cell therapy market 2 Cell therapy market growing >20% … BioLife expands our offering Ability to leverage our commercial org … cross-s

  7. Slide 7: BioLife Increases Our Presence in Cell Therapy, an Attractive & Rapidly Growing Market

    Sizable Piece of Biologics Pipeline 1,100+ global cell therapies in pipeline Following proteins, cell therapy is the #2 modality in biologics Healthy Commercial Demand Multiple Drivers of Future Growth Strong efficacy driving adoption and approvals Robust commercial outlook Three blockbuster therapi

  8. Slide 8: BioLife Accelerates the Expansion of Our Cell Therapy Offering

    ATF bioreactor intensification Broad & Growing Cell Therapy Portfolio Expands Customer Value Proposition Accelerates innovation and new products Expands customer investment and support Enables integrated solutions selling Accelerates Revenue Growth Expands cross-selling opportunities Leverages globa

  9. Slide 9: Attractive Deal Structure … Preserving Flexibility for Repligen

    Attractive Deal Structure … Preserving Flexibility for Repligen Deal Structure Highlights Consideration ~$1.5B enterprise value … 11x 2027E Revenue with an attractive EV/EBITDA multiple on a fully synergized basis(1) $564 million of cash and 7.2 million Repligen shares Exchange ratio: 1 BioLife shar

  10. Slide 10: We Believe This is a Financially Compelling Transaction

    We Believe This is a Financially Compelling Transaction (1) 2025 Revenue reflects a pro forma view for recent divestitures. (2) RGEN includes stock compensation expense in the calculation of adj. EBITDA (3) Pro forma for year 1 synergies of $20M Synergies Attractive Deal Financials PF(1) Revenue Gro

  11. Slide 11: Summary

    Adds deeply embedded solutions in CT workflow & commercial therapies Scalable platform with high-growth, high-margin, recurring consumables revenues in bioprocessing Summary: Acquisition of highly-differentiated cell processing leader … Strengthens Repligen with a one-step adjacency in the high-grow

  12. Slide 12: Appendix

    Appendix #) REPLIGEN

  13. Slide 13: Transaction Opportunity Overview

    Transaction Opportunity Overview … Strong Strategic Fit, Financially Compelling Strong Strategic Fit Fast-tracks cell therapy leadership, expands our presence in this high-growth market Adds deeply embedded solutions in cell therapy workflows & commercial therapies Combination benefits customers by

  14. Slide 14: Non-GAAP Measures of Financial Performance

    Non-GAAP Measures of Financial Performance This presentation includes certain “non-GAAP measures.” Please refer to the Company’s “Non-GAAP Measures of Financial Performance” included within the Company’s current and historical filings on Forms 8-K for more information on the use of non-GAAP measures

Repligen — Merger or Acquisition (July 2026) on 6ix